Please assess the completion status of the following clinical trial:

Trial Title: Effect of LASER Photobiomodulation Therapy on Chronic Pain and Opioid Weaning

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older.~* Taking prescribed opioid pain medications in an amount in excess of 30 Morphine Equivalent Dose (MED) for 6 months or longer.~* Have been recommended to wean or reduce their MED.~* Medically stable such that subject does not have unstable angina, COPD requiring supplemental oxygen, untreated or active cancer or similar conditions that would make participation difficult or unsafe.~* Compliant with all physician recommendations relating to medication usage.~* Ambulatory and able to use the toilet independently.~* Negative pregnancy test in subjects of childbearing potential~* Willing to attempt opioid pain medication taper.~* Competent to provide informed consent.~* Capable of understanding and completing study questionnaires.~* Subject willing to participate in the study for up to 12 weeks.~Exclusion Criteria:~* Not capable of understanding or completing study questionnaires.~* Lacking capacity to provide fully informed consent.~* Substance use disorder not in remission.~* Considering surgery or other invasive procedures that would take place during the study.~* Used isotretinoin (Accutane) within 6 months prior to study enrollment~* Cancer not in remission.~* Need of ongoing Transcutaneous Electrical Nerve Stimulation (TENS) therapy, massage therapy, chiropractic care or other treatments intended to remediate pain other than treatment in the Sharp Pain Program.~* A female who is pregnant or lactating, or of childbearing potential unless a medically acceptable method of birth control is in use.~* Any use of light-activated drugs (photodynamic therapy) or heat sensitive medications within 30 days of first treatment.~* Used an investigational drug/device therapy or participated in any clinical investigation relating to pain within 4 weeks prior to study enrollment.~* A psychiatric or psychological condition that would place undo stress on the subject, prevent full participation or compromise data collection.~* The subject is otherwise determined, based on the opinion of the Investigator, to be an unsuitable candidate for enrollment in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- ABAB (Type: OTHER): Treatment, either LASER (arm A) or LOW LEVEL LASER (arm B) will be provided 3 (not less than 2) days a week for three weeks at which time crossover into the alternate arm occurs (BABA to ABAB or ABAB to BABA).~ABAB initial period is active treatment - LASER.~Active Treatment:~LASER light is delivered to the skin and deeper tissues affected by pain using either a wand or glass roller ball. Ten to 25 Watts of LASER energy is delivered to the painful regions for 8 to 16 minutes depending on the size of the area treated and other factors such as skin pigmentation.
- BABA (Type: OTHER): Treatment, either LASER (arm A) or LOW LEVEL LASER (arm B) will be provided 3 (not less than 2) days a week for three weeks at which time crossover into the alternate arm occurs (BABA to ABAB or ABAB to BABA).~BABA initial period is sham treatment - LOW LEVEL LASER.~LOW LEVEL LASER treatment:~Low level LASER is provided in a similar fashion using LASER power levels (1 Watt) that produce warmth only at superficial skin levels.

Based on this trial design, predict the completion outcome and termination type (if applicable).